Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.

Stocchi F, Rascol O, Hauser RA, Huyck S, Tzontcheva A, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt DJ; Preladenant Early Parkinson Disease Study Group.

Neurology. 2017 Jun 6;88(23):2198-2206. doi: 10.1212/WNL.0000000000004003. Epub 2017 May 10.

PMID:
28490648
2.

Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.

D'Haens G, Reinisch W, Colombel JF, Panes J, Ghosh S, Prantera C, Lindgren S, Hommes DW, Huang Z, Boice J, Huyck S, Cornillie F; ENCORE investigators.

J Crohns Colitis. 2017 Jun 1;11(6):680-689. doi: 10.1093/ecco-jcc/jjw221.

PMID:
28025307
3.

Adjunctive preladenant: A placebo-controlled, dose-finding study in Japanese patients with Parkinson's disease.

Hattori N, Kikuchi M, Adachi N, Hewitt D, Huyck S, Saito T.

Parkinsonism Relat Disord. 2016 Nov;32:73-79. doi: 10.1016/j.parkreldis.2016.08.020. Epub 2016 Aug 27.

PMID:
27632893
4.

Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.

Sieper J, Rudwaleit M, Lenaerts J, Wollenhaupt J, Myasoutova L, Park SH, Song YW, Yao R, Huyck S, Govoni M, Chitkara D, Vastesaeger N.

Rheumatology (Oxford). 2016 Nov;55(11):1946-1953. Epub 2016 Jul 13.

PMID:
27411482
5.

Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.

Vastesaeger N, Kutzbach AG, Amital H, Pavelka K, Lazaro MA, Moots RJ, Wollenhaupt J, Zerbini CA, Louw I, Combe B, Beaulieu A, Schulze-Koops H, Dasgupta B, Fu B, Huyck S, Weng HH, Govoni M, Durez P.

Rheumatology (Oxford). 2016 Aug;55(8):1466-76. doi: 10.1093/rheumatology/kew179. Epub 2016 Apr 25.

6.

A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.

Sieper J, van der Heijde D, Dougados M, Maksymowych WP, Scott BB, Boice JA, Berd Y, Bergman G, Curtis S, Tzontcheva A, Huyck S, Weng HH.

Arthritis Rheumatol. 2015 Oct;67(10):2702-12. doi: 10.1002/art.39257.

7.

The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects.

Hastrup N, Khalilieh S, Dale DC, Hanson LG, Magnusson P, Tzontcheva A, Tseng J, Huyck S, Rosenberg E, Krogsgaard K.

Cytokine. 2015 Apr;72(2):197-203. doi: 10.1016/j.cyto.2015.01.002. Epub 2015 Feb 4.

PMID:
25661195
8.

Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease.

Factor SA, Wolski K, Togasaki DM, Huyck S, Cantillon M, Ho TW, Hauser RA, Pourcher E.

Mov Disord. 2013 Jun;28(6):817-20. doi: 10.1002/mds.25395. Epub 2013 Apr 15.

PMID:
23589371
9.

Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.

Cornely OA, Helfgott D, Langston A, Heinz W, Vehreschild JJ, Vehreschild MJ, Krishna G, Ma L, Huyck S, McCarthy MC.

Antimicrob Agents Chemother. 2012 May;56(5):2652-8. doi: 10.1128/AAC.05937-11. Epub 2012 Jan 30.

10.

Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial.

Gan TJ, Gu J, Singla N, Chung F, Pearman MH, Bergese SD, Habib AS, Candiotti KA, Mo Y, Huyck S, Creed MR, Cantillon M; Rolapitant Investigation Group.

Anesth Analg. 2011 Apr;112(4):804-12. doi: 10.1213/ANE.0b013e31820886c3. Epub 2011 Mar 8.

PMID:
21385988
11.

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial.

Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K.

Lancet Neurol. 2011 Mar;10(3):221-9. doi: 10.1016/S1474-4422(11)70012-6.

PMID:
21315654
12.

Determining times to maximum urine excretion of 1-aminopyrene after diesel exhaust exposure.

Huyck S, Ohman-Strickland P, Zhang L, Tong J, Xu XU, Zhang JJ.

J Expo Sci Environ Epidemiol. 2010 Nov;20(7):650-5. doi: 10.1038/jes.2010.29. Epub 2010 May 5.

PMID:
20442755
13.

Particle size coarsening induced by valve silicone in a metered dose inhaler.

Sherwood JK, Alex S, Salama G, Obenauer-Kutner L, Huyck S, Berry J, Sequeira J, Brouet G, Marie C.

Drug Dev Ind Pharm. 2007 Feb;33(2):155-62.

PMID:
17454047

Supplemental Content

Loading ...
Support Center